--- title: "MIRA highlights SKNY-1 preclinical data in new publication" type: "News" locale: "en" url: "https://longbridge.com/en/news/286256663.md" description: "MIRA Pharmaceuticals, Inc. announced the publication of a peer-reviewed manuscript on its investigational drug SKNY-1 for obesity and nicotine addiction in the International Journal of Molecular Sciences. The study shows SKNY-1's effects on weight loss and metabolic markers in zebrafish models, highlighting its potential as a novel treatment. However, the drug is not FDA-approved, and its safety and efficacy in humans are unestablished. Analysts rate MIRA stock as a Buy with a target price of $8.00, while the company continues to develop its pipeline targeting metabolic diseases and addiction." datetime: "2026-05-13T12:00:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286256663.md) - [en](https://longbridge.com/en/news/286256663.md) - [zh-HK](https://longbridge.com/zh-HK/news/286256663.md) --- # MIRA highlights SKNY-1 preclinical data in new publication ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks MIRA Pharmaceuticals, Inc. ( (MIRA) ) just unveiled an announcement. On May 13, 2026, MIRA Pharmaceuticals announced that a peer-reviewed manuscript on its investigational obesity and nicotine addiction drug SKNY-1 was published in the International Journal of Molecular Sciences. The paper details in vitro pharmacologic characterization and in vivo results in an MC4R-deficient zebrafish model, showing that SKNY-1 differentially engages CB1 pathways, acts as a partial CB2 agonist, and selectively inhibits MAO-B compared with MAO-A. The publication reports that oral SKNY-1 produced dose-dependent weight loss over six days, including about a 30% reduction from baseline at higher doses without significant loss of whole-body density. It further describes improvements in lipid profiles, reduced hepatic triglyceride accumulation, modulation of leptin and ghrelin gene expression, and reduced compulsive feeding and nicotine-seeking behaviors, while noting these findings are limited to zebrafish and in vitro systems and that SKNY-1 is not FDA-approved and its safety and efficacy in humans remain unestablished. MIRA also highlighted previously reported preclinical data indicating attenuation of anxiety-like behaviors in a zebrafish model, which the company views as consistent with SKNY-1’s differentiated CB1 pathway engagement. The publication underscores SKNY-1’s potential as a novel candidate at the intersection of metabolic disease and addiction, though its ultimate clinical and commercial impact will depend on future human studies and regulatory evaluation. The most recent analyst rating on (MIRA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page. **More about MIRA Pharmaceuticals, Inc.** MIRA Pharmaceuticals, Inc. is a biopharmaceutical company developing investigational oral drug candidates targeting obesity and nicotine addiction. Its pipeline includes SKNY-1, a tetrahydrocannabivarin (THCV) analog focused on modulating cannabinoid receptor pathways and metabolic markers in preclinical models, with an emphasis on weight management and addiction-related behaviors. **Average Trading Volume:** 153,554 **Technical Sentiment Signal:** Hold **Current Market Cap:** $42.86M Learn more about MIRA stock on TipRanks’ Stock Analysis page. ### Related Stocks - [MIRA.US](https://longbridge.com/en/quote/MIRA.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) ## Related News & Research - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md) - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [Neurothera Labs Announces Adoption of Semi-Annual Reporting](https://longbridge.com/en/news/287119698.md) - [BioMarin's drug shows significant growth gains in children in late-stage trial](https://longbridge.com/en/news/287121584.md)